Successful treatment of imatinib-induced periorbital edema with a sodium-glucose cotransporter-2 inhibitor

Benjamin Chin-Yee^{1

2}, Anargyros Xenocostas^{3

4}

Affiliations

¹ Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
² Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON, Canada.
³ Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. anargyros.xenocostas@lhsc.on.ca.
⁴ Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON, Canada. anargyros.xenocostas@lhsc.on.ca.

Benjamin Chin-Yee et al. Ann Hematol. 2022 Jun.

. 2022 Jun;101(6):1373-1374.

doi: 10.1007/s00277-021-04741-3. Epub 2022 Feb 2.

Benjamin Chin-Yee^{1

2}, Anargyros Xenocostas^{3

4}

¹ Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
² Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON, Canada.
³ Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. anargyros.xenocostas@lhsc.on.ca.
⁴ Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON, Canada. anargyros.xenocostas@lhsc.on.ca.

No abstract available

References

1. Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037 - DOI
1. Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J (2003) Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther 19:371–375 - DOI
1. Esmaeli B, Prieto VG, Butler CE et al (2002) Severe periorbital edema secondary to STI571 (Gleevec). Cancer 95:881–887 - DOI
1. Pietras K, Östman A, Sjöquist M et al (2001) Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Can Res 61:2929–2934
1. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128 - DOI